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To investigate the association of leprosy with hepatitis B virus (HBV) infection, as yet
unknown  for South Brazil, we assessed hepatitis B virus coinfection in 199 South Brazil-
ian  leprosy patients (119 lepromatous, 15 tuberculoid, 30 borderline, 12 undetermined and
23  unspeciﬁed) and in 681 matched blood donors by screening for the hepatitis B virus
markers  HBSAg and anti-HBc, using ELISA. Positive samples were retested and anti-HBc+
only  samples were tested for the hepatitis B surface antibody (anti-HBs). There was a
strong association between leprosy and hepatitis B virus infection (OR = 9.8, 95% CI = 6.4–14.7;
p  = 0.004·E−30), as well as an association between HBV infection and lepromatous leprosy,
compared  to other forms (OR = 2.4, 95% CI = 1.2–4.8; p = 0.017). We  also found that con-
ﬁnement  due to leprosy was associated with hepatitis B virus infection (OR = 3.9, 95%
CI  = 2.1–7.4; p = 0.015·E−3). Leprosy patients are susceptible to develop hepatitis B virus infec-
tion,  especially lepromatous. Institutionalized patients, who probably present a strongerTh2  response, have higher risk of being exposed to hepatitis B virus. This clearly empha-
sizes  the need for special care to leprosy patients in preventing hepatitis B virus coinfection
in  South Brazil.
of  former investigations, but nothing is known about this
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Leprosy is a long known infectious disease and still repre-
sents  a major cause of morbidity and mortality in developing
countries. According to data of the World Health Organization,
more  than 30,000 people are affected in the Americas.2 In 2012
alone,  there were  406 new admissions to Brazilian hospitals
due  to leprosy. In South Brazil, 36,628 patients were diagnosed
with  the disease in 2011 and 10.9% presented grade 2 disability
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Este é um artigo Open Access sob a licença(11.4% in Paraná state), which is the highest rate in the coun-
try.  South Brazil also has the 7th highest rate in Brazil of new
case  detection of leprosy with incapacity: 93.8%.1
Many leprosy patients also have positive markers for other
infections,  such as HIV and HBV (hepatitis B virus).3–7 In cen-
tral  Brazil, leprosy along with hepatitis B has been the subject
6,7 Department of Medical Pathology, Hospital de Clínicas, Federal
, Brazil.
disease  association in other Brazilian regions. In this work,
we  aimed to describe leprosy–HBV epidemiology in South
Brazil.
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aterials  and  methods
ubjects  and  samples
wo hundred and three patients with leprosy from three dif-
erent  treatment centers were selected. Twenty-three of them
ere  attended at Universidade Federal do Paraná’s Clinical
ospital  (HC-UFPR), 71 at Paraná’s Hospital of Sanitary Derma-
ology  (PHSD) and 109 at Regional Center of Specialities-Barão
CRS-Barão). The patients from now on referred as “institu-
ionalized” are 60 patients hospitalized permanently in PHSD.
he  high prevalence of institutionalized patients is explained
y  their social conditions. Since they presented advanced
orms of leprosy or were  abandoned by their families, con-
nement  was  the best way  to assist them. Four patients
ad  to be excluded from the study. Two of them did not
how  up to have their blood samples taken, and access to
he  medical records was  not possible for another two. Thus,
99  patients were  designated as “cases” for all analysis pur-
oses.
The  patients were also divided in groups according to
he  clinical classiﬁcation proposed by Ridley and Jopling.8
iagnosis at presentation was  lepromatous leprosy for 119
atients  (59.8%), tuberculoid leprosy for 15 (7.5%), and border-
ine  leprosy for 30 patients (15.1%); 12 patients (6%) had an
ndetermined form of leprosy, and 23 (11.6%) were unspeci-
ed.  Those with unspeciﬁed form of the disease were excluded
rom  the analysis of clinical forms (176 cases were  consid-
red).
Six  hundred and eighty-one blood donors tested for anti-
Bc  from HC-UFPR Hemotherapy Service were  selected as
ontrols.  Cases (average age of 52 ± 16 years) and controls
average age of 45 ± 12 years) were  also matched for age-
ange  groups. The ﬁrst group comprised nine patients and 36
ontrols  between 15 and 24 years of age. The second group
ad  75 patients and 200 controls between 25 and 49 years,
nd  the third one, 115 cases and 345 controls above 50 years
ld.  77 (38.7%) patients and 269 (39.5%) controls were female,
hereas  122 (61.3%) patients and 412 (60.5%) controls were
ale.
Patients  and controls were selected in 2002 and 2003. The
tudy  was  approved by the ethics committee of the Clinic Hos-
ital  and Health State Department, and all subjects were asked
o  give written an informed consent for their participation and
o  answer a standardized questionnaire to determine the his-
ory of the patients regarding possible blood transfusion and
he  existence of other infectious diseases.
Table 1 – Different HBV infection markers in leprosy patients an
Patients (%) 
n 199 
HBsAg only 2 (1) 
HBsAg and anti-HBc 3 (1.5) 
Anti-HBc only 24 (12.1) 
Anti-HBc and anti-HBs 50 (25.1) 
Total 79 
n, number of individuals. 0 1 4;1 8(1):8–12  9
HBV  testing
Seven mL  of blood were  taken from each subject. The samples
were  centrifuged and serum aliquots stored at −20 ◦C before
HBV  testing. An ELISA was  used to detect the presence of anti-
HBc  (antibodies against HBV core antigen) (MONOLISA® a-HBc
PLUS,  BIO-RAD, Marnes La Coquette, France). To search for
HBsAg,  a sandwich ELISA was  performed (MONOLISA® a-HBc
PLUS,  BIO-RAD, Marnes La Coquette, France). Patients positive
for  anti-HBc alone (HBsAg negative) were tested by microparti-
cle  enzyme immunoassay (MEIA) to detect antibodies against
hepatitis  B surface antigen (anti-HBs) (Murex anti-HBs, Murex
Biotech  Limited, Temple Hill, United Kingdom). All positive
samples  were  retested using the same methods.
Statistics
Frequencies were compared using Fisher’s exact test and
odds  ratios with the respective 95% conﬁdence limits. Logistic
regression  models were used to adjust results for age, gender
and  assistance using the SPSS 13.0 software (IBM, USA).
Results
Of the leprosy patients, 39.7% were  positive for HBV markers,
in  contrast to 6.3% of the control group (Table 1), suggest-
ing  a strong association between leprosy and HBV infection
(79/199  vs. 43/681; OR = 9.77, 95% CI = 6.42–14.86; p < 0.004·E−30).
Of  the leprosy patients, 26 (13.1%) received blood transfu-
sion,  of which twelve were  positive for HbsAg and/or anti-HBc.
Even  after the exclusion of these possibly intravenously
HBV-infected patients, leprosy and HBV infection remained
associated (67/173 vs. 43/681; OR = 9.38, 95% CI = 6.08–14.48;
p  = 0.006·E−24). There was no difference for HBV positivity
according to gender and age (p = 0.117, Table 2). The follow-
ing  co-infections were also observed in HBV+ leprosy patients:
seven  were  positive for syphilis, six for HCV, two for Chagas
disease,  one for HCV and syphilis and one for syphilis and
Chagas  disease.
There  was also an association between HBV infection
and lepromatous leprosy, compared with the other leprosy
forms  (unspeciﬁed patients were excluded) (55/119 or 46.2%
vs.  15/57 or 26.3%; OR = 2.4, 95% CI = 1.2–4.8; p = 0.017·E−30, see
Table  3). This remained signiﬁcant in the logistic regression
after  correction for age and gender and was  independent of
conﬁnement  (p = 0.018). We  also found that conﬁnement due
to  leprosy was associated with HBV infection (38/61 or 62.3%
d controls.
Controls (%) Institutionalized (%)
681 60
0 (0) 0
1 (0.15) 1 (1.6)
12 (1.76) 14 (23.3)
30 (4.41) 21 (35)
43 36
10  b r a z j i n f e c t d i s . 2 0 1 4;1  8(1):8–12
Table 2 – Prevalence of HBV positivity according to gender and age.
Patients (%) Controls (%)
HBV− HBV+ HBV− HBV+
n 120 (39.7) 79 (60.3) 638 (93.7) 43 (6.3)
Gender
M 71 (59.2) 51 (64.6) 385 (60.3) 27 (62.8)
F 49 (40.8) 28 (35.4) 253 (39.7) 16 (37.2)
Age
15–24 8 (6.6) 1 (1.3) 36 (5.6) 0 (0)
25–49 48 (40) 27 (34.2) 287 (45) 13 (30.2)
>50 64 (53.3) 51 (64.5) 315 (49.4) 30 (69.8)n, number of individuals.
vs. 41/138 or 29.7%; OR = 3.9, 95% CI = 2.1–7.4; p = 0.015·E−3).
This  result does also remain signiﬁcant after correction for age
and gender and was  independent of the lepromatous status
(p  < 0.0001). Two years after taking blood samples, the eval-
uation  of conﬁned HBV+ patients (38) showed that: 17 were
released  (9 women  and 8 man; mean age = 63), 12 were  still
conﬁned  (4 women  and 8 men; mean age = 46 years) and 8
passed  away (1 woman  and 7 men; mean age = 73). Seven
patients of HC-UFPR out clinic were  HBV+, one of them was
still  there (an 87 year-old man), two had to be conﬁned (one
man  and one woman; mean age = 66) and three passed away
(two  women  and one man; mean age = 67). One of them pre-
sented  a sudden and intense jaundice, dying a few days later.
Discussion
The positive association between leprosy and HBV infection
has  been repeatedly reported since the 1970s,6,9–20 although
absence of association has also been found.21–27 Prevalence of
HBV–leprosy  co-infection depends on many  factors, such as
local  endemicity and the sensitivity of methods used for HBV
detection.  Many  authors considered only the prevalence of
HBsAg.9,12,13,15,20,24,25,28,29 Others determined the prevalence
of HBsAg and anti-HBs,14,17,19,22,30,31 whereas some screened
only for anti-HBc.6,16,32 In contrast, we  considered as HBV
infected, patients having an active infection (HBsAg posi-
tive  only, or anti-HBc and HBsAg positive) and patients who
were  exposed to the virus, with or without developing speciﬁc
antibodies  against it (positive for anti-HBc and/or anti-HBs).
Table 3 – Prevalence of HBV positivity according to
different  clinical forms of leprosy in patients from
southern Brazil.
HBV− (%) HBV+ (%)
n 105 70
Lepromatous 64 (60.9) 55 (78.6)
Tuberculoid 14 (13.3) 1 (1.4)
Boderline 21 (20.0) 9 (12.9)
Indetermined 6 (05.7) 5 (7.1)
All the unspeciﬁed-clinical patients were excluded. n, number of
individuals.HBsAg or anti-HBc only results could be false positive, how-
ever,  and patients with these results should thus be closely
followed.33
In a recent study conducted in central Brazil, 25.5% of lep-
rosy  patients were  positive for serological HBV markers and
2.6%  had active disease.7 These ﬁgures were very similar to
the  results with a much  larger leprosy population in Sene-
gal  (n = 987).19 Between 1973 and 1977, the prevalence of HBV
positivity  in that setting was  25.5% and between 1982 and
1986,  it was  23.0%. Thus HBV/leprosy co-infection is not exclu-
sive  to southern Brazil. Nevertheless, we encountered a much
stronger  association (60.3% of co-infection), possibly because
of  epidemiological differences and/or different sensitivity of
HBV  detection assays (radioimmunoassay vs. enzyme linked
immunoassay).
As  previously stated by others, there was  no relevant
association between co-infection and gender.10,19 This sug-
gests  that the susceptibility to leprosy/HBV co-infection is
not  directly linked to genes on the X chromosome or asso-
ciated  to sex-speciﬁc hormones. Also, analyzing age groups,
we  found that both leprosy patients and control groups show
the  same pattern of HBV infection. Age seems not to inﬂuence
co-infection, as there was  no difference in the distribution of
co-infected  cases according to age groups.
The higher prevalence of HBV positivity in patients with
the  lepromatous form of the disease was also expected.34,35
Lepromatous leprosy is characterized by a Th2-type immune
response.36 This pattern of inﬂammatory response is also
responsible for lowering the viral clearance of HBV.37 Thus,
lepromatous leprosy patients are probably unable to perform
a  satisfactory clearance of HBV, becoming vulnerable to co-
infection.
We  also conﬁrmed the higher prevalence of HBV infection
in  patients kept in “leprosariums”.6,13,22 Since hepatitis B is
transmitted person-to-person via body ﬂuids,21 patients who
are  conﬁned have higher risk to be infected, because HBV pos-
itive  and HBV negative subjects share the same space. It is
interesting  that Rosa et al. also found that institutionalized
patients in central Brazil had almost fourfold risk of being HBV
infected,  if compared to outpatients.6
Thus, leprosy/HBV co-infection is not uncommon in South
Brazil.  Leprosy patients are susceptible to develop HBV infec-
tion,  especially lepromatous and institutionalized patients,
who  probably present a higher risk of being exposed to the
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BV. This clearly emphasizes the need for special care to lep-
osy  patients in preventing HBV co-infection.
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